吉西他滨联合替吉奥治疗晚期胰腺癌的疗效观察  

Analysis of the Clinical Value of Gemcitabine Combined with S-1 in Patients with Pancreatic Cancer

作　　者：王晓友[1] 黄广清[1] 赵晶[1] 汪海岩[1] 杜秀平[1] 

机构地区：[1]徐州医学院附属医院肿瘤中心,江苏徐州221002

出　　处：《中国医药指南》2014年第33期10-11,共2页Guide of China Medicine

摘　　要：目的探究吉西他滨和替吉奥联合在晚期胰腺癌治疗中的临床价值,并在临床工作中进行推广使用。方法选取在我院进行治疗的晚期胰腺癌患者34例,分为观察组和对照组两组,每组17例。观察组患者应用吉西他滨联合替吉奥进行治疗,而对照组患者应用吉西他滨单药进行治疗,观察两组患者治疗的有效率以及不良反应发生率,并进行比较。结果观察组患者的总有效率明显高于对照组患者,差异均具有统计学意义(P<0.05),而不良反应的发生率以及生存时间的差异无统计学意义(P>0.05)。结论采用吉西他滨与替吉奥联合治疗治疗晚期胰腺癌,在不增加不良反应的基础上,可以提高治疗的有效率,具有重要的临床应用价值。Objective To explore the clinical value of gemcitabine combined with S-1 in patients with pancreatic cancer, and it should be widely used in clinical work. Methods Selected 34 cases of patients with pancreatic cancer, and we divided them into the control group and the observation group, 17 cases in each group. The patients in observation group received gemcitabine combined with S-1 for treatment, while the control group were treated with gemcitabine, and we recorded the efficiency and adverse reaction rate, then we compared. Results The total effective rate of the observation group was significantly higher than that of the control group, and the differences were statistically significant （P〈0.05）. And compared the adverse reaction rate of the two groups, there was no statistically significance （P〉0.05）. Conclusion For patients with pancreatic cancer, gemcitabine combined with S-1 for treatment can improve the treatment efficiency, which has important value in clinical application.

关 键 词：胰腺癌 吉西他滨 替吉奥 

分 类 号：R735.9[医药卫生—肿瘤]